You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePrazosin
Accession NumberDB00457  (APRD00020)
TypeSmall Molecule
GroupsApproved
DescriptionPrazosin is a selective α-1-adrenergic receptor antagonist used to treat hypertension. It has also been used to decrease urinary obstruction and relieve symptoms associated with symptomatic benign prostatic hyperplasia. α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. Prazosin has also been used in conjunction with cardiac glycosides and diuretics in the management of severe congestive heart failure. It has also been used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma.
Structure
Thumb
Synonyms
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
Prazosina
Prazosine
Prazosinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-prazosin-tab 1mgTablet1 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-prazosin-tab 2mgTablet2 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-prazosin-tab 5mgTablet5 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
MinipressCapsule2 mg/1OralPfizer Laboratories Div Pfizer Inc1994-05-10Not applicableUs
MinipressTablet1 mgOralErfa Canada 2012 Inc1983-12-31Not applicableCanada
MinipressTablet2 mgOralErfa Canada 2012 Inc1983-12-31Not applicableCanada
MinipressCapsule5 mg/1OralPfizer Laboratories Div Pfizer Inc1994-05-10Not applicableUs
MinipressCapsule1 mg/1OralPfizer Laboratories Div Pfizer Inc1994-05-10Not applicableUs
MinipressTablet5 mgOralErfa Canada 2012 Inc1983-12-31Not applicableCanada
Nu-prazo Tab 1mgTablet1 mgOralNu Pharm Inc1992-12-312012-09-04Canada
Nu-prazo Tab 2mgTablet2 mgOralNu Pharm Inc1992-12-312012-09-04Canada
Nu-prazo Tab 5mgTablet5 mgOralNu Pharm Inc1992-12-312012-09-04Canada
Prazosin-1 Tab 1mgTablet1 mgOralPro Doc Limitee1991-12-312009-07-23Canada
Prazosin-2 Tab 2mgTablet2 mgOralPro Doc Limitee1991-12-312009-07-23Canada
Prazosin-5 TabTablet5 mgOralPro Doc Limitee1991-12-312009-07-23Canada
Rho-prazosin - Tab 1mgTablet1 mgOralRhodiapharm Inc1995-12-311998-08-05Canada
Rho-prazosin - Tab 5mgTablet5 mgOralRhodiapharm Inc1995-12-311998-08-05Canada
Rho-prazosin-tab 2mgTablet2 mgOralRhodiapharm Inc1995-12-311998-08-05Canada
Teva-prazosinTablet1 mgOralTeva Canada Limited1992-12-31Not applicableCanada
Teva-prazosinTablet2 mgOralTeva Canada Limited1992-12-31Not applicableCanada
Teva-prazosinTablet5 mgOralTeva Canada Limited1992-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-prazo Tab 1mgTablet1 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-prazo Tab 2mgTablet2 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-prazo Tab 5mgTablet5 mgOralApotex Inc1990-12-31Not applicableCanada
Prazosin HydrochlorideCapsule5 mg/1OralREMEDYREPACK INC.2011-04-21Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralMylan Pharmaceuticals Inc.1989-02-28Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralLake Erie Medical DBA Quality Care Products LLC1989-02-28Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralAidarex Pharmaceuticals LLC2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralA S Medication Solutions2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule5 mg/1OralREMEDYREPACK INC.2016-01-22Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralREMEDYREPACK INC.2013-05-28Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralAphena Pharma Solutions Tennessee, Inc.2009-12-21Not applicableUs
Prazosin HydrochlorideCapsule5 mg/1OralTeva Pharmaceuticals Usa, Inc.2007-01-18Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralA S Medication Solutions2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralMylan Institutional Inc.1998-10-05Not applicableUs
Prazosin HydrochlorideCapsule5 mg/1OralMylan Pharmaceuticals Inc.1989-02-28Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1Oralbryant ranch prepack2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralAidarex Pharmaceuticals LLC2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralA S Medication Solutions1989-02-28Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralREMEDYREPACK INC.2013-05-28Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralCardinal Health1998-10-05Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralAphena Pharma Solutions Tennessee, Llc2013-05-17Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralREMEDYREPACK INC.2011-11-14Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralA S Medication Solutions2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralMylan Institutional Inc.1998-10-06Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralTYA Pharmaceuticals2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule5 mg/1OralPd Rx Pharmaceuticals, Inc.2010-02-10Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralTeva Pharmaceuticals Usa, Inc.2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralREMEDYREPACK INC.2009-02-12Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralREMEDYREPACK INC.2010-10-11Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralMylan Pharmaceuticals Inc.1989-02-28Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralCarilion Materials Management2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule5 mg/1OralMylan Institutional Inc.1998-10-06Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralPd Rx Pharmaceuticals, Inc.2010-02-10Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralTeva Pharmaceuticals Usa, Inc.2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralPhysicians Total Care, Inc.2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralA S Medication Solutions2007-02-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HypovaseNot Available
Minipress XlPfizer
PressinNot Available
VasoflexNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Prazosin Hydrochloride
19237-84-4
Thumb
  • InChI Key: WFXFYZULCQKPIP-UHFFFAOYSA-N
  • Monoisotopic Mass: 419.136031924
  • Average Mass: 419.862
DBSALT000329
Categories
UNIIXM03YJ541D
CAS number19216-56-9
WeightAverage: 383.4011
Monoisotopic: 383.159354185
Chemical FormulaC19H21N5O4
InChI KeyIENZQIKPVFGBNW-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
IUPAC Name
2-[4-(furan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
Pharmacology
IndicationFor treatment of hypertension, symptomatic benign prostatic hyperplasia, and severe congestive heart failure. May also be used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma.
Structured Indications
PharmacodynamicsPrazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Prazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Prazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Prazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Prazosin results from a decrease in systemic vascular resistance and the parent compound Prazosin is primarily responsible for the antihypertensive activity.
Mechanism of actionPrazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-1A adrenergic receptorProteinyes
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinyes
antagonist
HumanP35368 details
Alpha-1D adrenergic receptorProteinyes
antagonist
HumanP25100 details
Potassium voltage-gated channel subfamily H member 2Proteinunknown
inhibitor
HumanQ12809 details
Potassium voltage-gated channel subfamily H member 6Proteinunknown
inhibitor
HumanQ9H252 details
Potassium voltage-gated channel subfamily H member 7Proteinunknown
inhibitor
HumanQ9NS40 details
Alpha-2A adrenergic receptorProteinunknown
binder
HumanP08913 details
Alpha-2B adrenergic receptorProteinunknown
binder
HumanP18089 details
Related Articles
AbsorptionWell-absorbed from gastrointestinal tract; bioavailability is variable (50 to 85%).
Volume of distributionNot Available
Protein binding97%
Metabolism

Primarily hepatic. Several metabolites have been identified in humans and animals (6- O -demethyl, 7- O -demethyl, 2-[1-piperazinyl]-4-amino-6, 7-dimethoxyquinazoline, 2,4-diamino-6,7-dimethoxyquinazoline).

SubstrateEnzymesProduct
Prazosin
Not Available
2,4-diamino-6,7-dimethoxyquinazolineDetails
Prazosin
Not Available
6-O-demethyl,7-O-demethyl,2-[1-piperazinyl]-4-amino-6,7-dimethoxyquinazolineDetails
Route of eliminationAnimal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by demethylation and conjugation, and excreted mainly via bile and feces. Less extensive human studies suggest similar metabolism and excretion in man.
Half life2-3 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Prazosin.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Prazosin.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Prazosin.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Prazosin is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Prazosin.Approved, Vet Approved
AdrafinilPrazosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Prazosin.Approved
AlbendazoleThe serum concentration of Prazosin can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Prazosin.Approved
AldosteroneThe serum concentration of Prazosin can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Prazosin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Prazosin can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Prazosin.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Prazosin is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Prazosin.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Withdrawn
AmantadineThe serum concentration of Prazosin can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Prazosin.Approved, Investigational
AmifostinePrazosin may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Prazosin is combined with Amiloride.Approved
Aminohippuric acidThe serum concentration of Prazosin can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Prazosin can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitrazPrazosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Prazosin.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Prazosin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Prazosin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Prazosin is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Prazosin can be decreased when it is combined with Amprenavir.Approved
AmrinonePrazosin may increase the hypotensive activities of Amrinone.Approved
AmsacrineThe serum concentration of Prazosin can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Prazosin is combined with Amyl Nitrite.Approved
AnisodaminePrazosin may decrease the vasoconstricting activities of Anisodamine.Investigational
Aop200704Aop200704 may increase the orthostatic hypotensive activities of Prazosin.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Prazosin.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Prazosin is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Apraclonidine.Approved
ArbutaminePrazosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolPrazosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Prazosin.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Prazosin.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Prazosin.Approved, Investigational
AstemizoleThe serum concentration of Prazosin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Prazosin.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Prazosin.Approved
AtorvastatinThe serum concentration of Prazosin can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Prazosin.Approved, Investigational
AzelastineThe serum concentration of Prazosin can be increased when it is combined with Azelastine.Approved
AzelnidipinePrazosin may increase the hypotensive activities of Azelnidipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Prazosin is combined with Azilsartan medoxomil.Approved
AzimilidePrazosin may increase the hypotensive activities of Azimilide.Investigational
AzithromycinThe serum concentration of Prazosin can be increased when it is combined with Azithromycin.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Prazosin.Experimental
BarbitalBarbital may increase the hypotensive activities of Prazosin.Illicit
BarnidipinePrazosin may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Prazosin.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Prazosin.Approved
BenidipinePrazosin may increase the hypotensive activities of Benidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Prazosin.Withdrawn
BenzocaineThe serum concentration of Prazosin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Prazosin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Prazosin.Approved, Vet Approved
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Prazosin.Approved
BethanidineBethanidine may increase the hypotensive activities of Prazosin.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Prazosin.Approved
BimatoprostPrazosin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Prazosin can be increased when it is combined with Biperiden.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Prazosin.Approved
BitolterolPrazosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Prazosin.Approved
BopindololBopindolol may increase the orthostatic hypotensive activities of Prazosin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Prazosin is combined with Bortezomib.Approved, Investigational
BosentanPrazosin may increase the hypotensive activities of Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Prazosin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Prazosin.Approved
BretyliumThe risk or severity of adverse effects can be increased when Prazosin is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Prazosin.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Prazosin.Approved, Investigational
BucindololPrazosin may increase the antihypertensive activities of Bucindolol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Prazosin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Prazosin is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Prazosin is combined with Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Prazosin.Approved
BuprenorphineThe serum concentration of Prazosin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Prazosin can be increased when it is combined with Bupropion.Approved
BuspironeThe serum concentration of Prazosin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Prazosin.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Prazosin.Approved
CaiPrazosin may increase the hypotensive activities of Cai.Investigational
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Prazosin.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Prazosin is combined with Candesartan.Approved
CandoxatrilPrazosin may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Captopril.Approved
CarbamazepineThe serum concentration of Prazosin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Prazosin is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Prazosin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Prazosin.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Prazosin.Approved
CarvedilolPrazosin may increase the antihypertensive activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Prazosin can be increased when it is combined with Caspofungin.Approved
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Prazosin.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Prazosin.Withdrawn
ChloroquineThe serum concentration of Prazosin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Prazosin is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Prazosin.Approved, Vet Approved
ChlorpropamideThe serum concentration of Prazosin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Prazosin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Prazosin.Approved
CholesterolThe serum concentration of Prazosin can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Prazosin can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Cilazapril.Approved
CilnidipinePrazosin may increase the hypotensive activities of Cilnidipine.Approved
CimetidineThe serum concentration of Prazosin can be decreased when it is combined with Cimetidine.Approved
CinnarizinePrazosin may increase the hypotensive activities of Cinnarizine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Prazosin.Approved, Investigational
CirazolinePrazosin may decrease the vasoconstricting activities of Cirazoline.Experimental
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Prazosin.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Prazosin.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Prazosin.Approved
ClenbuterolPrazosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Prazosin is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Prazosin.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Prazosin is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Prazosin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Prazosin.Approved, Investigational
ClomipramineThe serum concentration of Prazosin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Clonidine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Prazosin.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Prazosin can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Prazosin.Approved
CobicistatThe serum concentration of Prazosin can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Prazosin.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Prazosin.Approved
ColforsinThe serum concentration of Prazosin can be increased when it is combined with Colforsin.Experimental
ConivaptanThe risk or severity of adverse effects can be increased when Prazosin is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Prazosin.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Prazosin.Approved
CryptenaminePrazosin may increase the hypotensive activities of Cryptenamine.Approved
CyclophosphamideThe serum concentration of Prazosin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Prazosin can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazidePrazosin may increase the hypotensive activities of Cyclothiazide.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Prazosin.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Prazosin.Approved
DaclatasvirThe serum concentration of Prazosin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Prazosin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Prazosin is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Prazosin.Investigational
DarodipinePrazosin may increase the hypotensive activities of Darodipine.Experimental
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Prazosin.Approved, Investigational
DaunorubicinThe serum concentration of Prazosin can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Prazosin.Approved
DeserpidinePrazosin may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Prazosin is combined with Desflurane.Approved
DesipramineThe serum concentration of Prazosin can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Prazosin can be increased when it is combined with Desloratadine.Approved, Investigational
DetomidinePrazosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Prazosin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe serum concentration of Prazosin can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Prazosin.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Prazosin.Approved
DiclofenacThe serum concentration of Prazosin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Prazosin is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Prazosin.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Prazosin.Approved
DigoxinThe serum concentration of Prazosin can be decreased when it is combined with Digoxin.Approved
DihydralazinePrazosin may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Prazosin can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Prazosin.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Prazosin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Prazosin is combined with Dinutuximab.Approved
DipivefrinPrazosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Prazosin is combined with Dipyridamole.Approved
DobutaminePrazosin may decrease the vasoconstricting activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Prazosin.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Prazosin.Approved, Investigational, Vet Approved
DorzolamidePrazosin may increase the hypotensive activities of Dorzolamide.Approved
DotarizinePrazosin may increase the hypotensive activities of Dotarizine.Investigational
DoxazosinPrazosin may increase the antihypertensive activities of Doxazosin.Approved
DoxepinThe serum concentration of Prazosin can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Prazosin.Approved, Investigational
DoxorubicinThe serum concentration of Prazosin can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Prazosin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Prazosin can be increased when it is combined with Dronedarone.Approved
DroxidopaPrazosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetinePrazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Prazosin.Approved
EfonidipinePrazosin may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Prazosin can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Prazosin.Approved, Investigational
EltrombopagThe serum concentration of Prazosin can be increased when it is combined with Eltrombopag.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Enalapril.Approved, Vet Approved
EnalaprilatPrazosin may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Prazosin can be increased when it is combined with Enzalutamide.Approved
EperisonePrazosin may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedrinePrazosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Prazosin.Approved, Investigational
EpinephrinePrazosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Prazosin is combined with Eplerenone.Approved
EpoprostenolPrazosin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Prazosin is combined with Eprosartan.Approved
ErgonovineThe serum concentration of Prazosin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Prazosin can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Prazosin.Approved, Investigational
ErythromycinThe serum concentration of Prazosin can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Prazosin.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Prazosin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Prazosin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Prazosin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Prazosin can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Prazosin is combined with Etacrynic acid.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Prazosin.Approved
EtilefrinePrazosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtoposideThe serum concentration of Prazosin can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Prazosin can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Prazosin.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Prazosin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Prazosin is combined with Felodipine.Approved, Investigational
FendilinePrazosin may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamPrazosin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolPrazosin may decrease the vasoconstricting activities of Fenoterol.Approved
FentanylThe serum concentration of Prazosin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Prazosin.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Prazosin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Prazosin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Prazosin is combined with Fimasartan.Approved
FluconazoleThe serum concentration of Prazosin can be increased when it is combined with Fluconazole.Approved
FlunarizinePrazosin may increase the hypotensive activities of Flunarizine.Approved
FluoxetineThe serum concentration of Prazosin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Prazosin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Prazosin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Prazosin can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Prazosin.Approved
FluvoxamineThe serum concentration of Prazosin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolPrazosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Prazosin.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Prazosin is combined with Furosemide.Approved, Vet Approved
GabapentinPrazosin may increase the hypotensive activities of Gabapentin.Approved, Investigational
GallopamilPrazosin may increase the hypotensive activities of Gallopamil.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Prazosin.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Prazosin.Approved
GenisteinThe serum concentration of Prazosin can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Prazosin can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Prazosin can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Prazosin can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Prazosin.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Prazosin.Withdrawn
GuanabenzPrazosin may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Prazosin.Approved
GuanethidinePrazosin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Prazosin is combined with Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Prazosin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Prazosin is combined with Halothane.Approved, Vet Approved
HexamethoniumPrazosin may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Prazosin.Approved
HexoprenalinePrazosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenaminePrazosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Prazosin.Approved
HydralazineThe risk or severity of adverse effects can be increased when Prazosin is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Prazosin is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Prazosin.Approved, Vet Approved
HydroflumethiazidePrazosin may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Prazosin.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Prazosin.Approved
IloprostIloprost may increase the hypotensive activities of Prazosin.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Prazosin.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Prazosin.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Prazosin.Approved
IndapamideThe risk or severity of adverse effects can be increased when Prazosin is combined with Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Prazosin.Withdrawn
IndinavirThe serum concentration of Prazosin can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Prazosin.Approved, Investigational
IndoraminPrazosin may increase the antihypertensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Prazosin.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Prazosin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Prazosin is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Prazosin.Approved, Investigational
IsavuconazoniumThe serum concentration of Prazosin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Prazosin.Approved
IsoetarinePrazosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Prazosin is combined with Isoflurane.Approved, Vet Approved
IsoprenalinePrazosin may decrease the vasoconstricting activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Prazosin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Prazosin.Approved
ItraconazoleThe serum concentration of Prazosin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Prazosin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Prazosin.Approved, Vet Approved
KetamineThe serum concentration of Prazosin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinPrazosin may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Prazosin.Approved
KetoconazoleThe serum concentration of Prazosin can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolPrazosin may increase the antihypertensive activities of Labetalol.Approved
LacidipinePrazosin may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Prazosin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Prazosin.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Prazosin.Approved, Investigational
LapatinibThe serum concentration of Prazosin can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostPrazosin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Prazosin.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Prazosin.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Prazosin.Approved
LercanidipinePrazosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Prazosin.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Prazosin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Prazosin is combined with Levobupivacaine.Approved
LevodopaPrazosin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Prazosin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Prazosin.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Prazosin is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Prazosin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Prazosin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Prazosin.Approved
LiothyronineThe serum concentration of Prazosin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Prazosin can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Lisinopril.Approved, Investigational
LofexidinePrazosin may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Prazosin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Prazosin.Approved
LopinavirThe serum concentration of Prazosin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Prazosin can be increased when it is combined with Loratadine.Approved
LosartanThe risk or severity of adverse effects can be increased when Prazosin is combined with Losartan.Approved
LovastatinThe serum concentration of Prazosin can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Prazosin can be decreased when it is combined with Lumacaftor.Approved
MacitentanPrazosin may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfatePrazosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
ManidipinePrazosin may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Prazosin is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Prazosin can be increased when it is combined with Maprotiline.Approved
MebanazineMebanazine may increase the hypotensive activities of Prazosin.Withdrawn
MebendazoleThe serum concentration of Prazosin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Prazosin is combined with Mecamylamine.Approved
MedetomidinePrazosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MefloquineThe serum concentration of Prazosin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Prazosin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MephenterminePrazosin may decrease the vasoconstricting activities of Mephentermine.Approved
MeprobamateThe serum concentration of Prazosin can be increased when it is combined with Meprobamate.Approved, Illicit
MetaraminolPrazosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethadoneThe serum concentration of Prazosin can be increased when it is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Prazosin is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Prazosin.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Prazosin.Approved
MethoxaminePrazosin may decrease the vasoconstricting activities of Methoxamine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Prazosin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Prazosin is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Prazosin.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Prazosin.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Prazosin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Prazosin.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Prazosin is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Prazosin is combined with Metolazone.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Investigational
MetyrosinePrazosin may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe serum concentration of Prazosin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Prazosin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Prazosin can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrinePrazosin may decrease the vasoconstricting activities of Midodrine.Approved
MifepristoneThe serum concentration of Prazosin can be decreased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Prazosin.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Prazosin.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Prazosin.Approved
MitomycinThe serum concentration of Prazosin can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Prazosin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Prazosin.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Prazosin.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Prazosin.Approved, Investigational
MoxonidinePrazosin may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Prazosin.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Prazosin is combined with Nabilone.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Prazosin.Approved
NaftopidilPrazosin may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Prazosin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Prazosin.Approved, Vet Approved
NaltrexoneThe serum concentration of Prazosin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolinePrazosin may decrease the vasoconstricting activities of Naphazoline.Approved
NaringeninThe serum concentration of Prazosin can be increased when it is combined with Naringenin.Experimental
NebivololThe risk or severity of adverse effects can be increased when Prazosin is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Prazosin can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Prazosin can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Prazosin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Prazosin is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Prazosin.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Prazosin is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Prazosin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Prazosin is combined with Nifedipine.Approved
NiguldipinePrazosin may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Prazosin.Approved, Investigational
NiludipinePrazosin may increase the hypotensive activities of Niludipine.Experimental
NilvadipinePrazosin may increase the hypotensive activities of Nilvadipine.Approved
NimesulidePrazosin may increase the hypotensive activities of Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Prazosin.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Prazosin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Prazosin.Approved
NitrazepamThe serum concentration of Prazosin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Prazosin can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Prazosin is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Prazosin is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Prazosin.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Prazosin.Approved
NorepinephrinePrazosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorethisteroneThe serum concentration of Prazosin can be decreased when it is combined with Norethisterone.Approved
NylidrinPrazosin may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabPrazosin may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Prazosin.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Prazosin.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Prazosin.Approved, Investigational
OlodaterolPrazosin may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatPrazosin may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Prazosin.Approved
OmeprazoleThe serum concentration of Prazosin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalinePrazosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Prazosin.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Prazosin.Approved
OxymetazolinePrazosin may decrease the vasoconstricting activities of Oxymetazoline.Approved
P-NitrophenolThe serum concentration of Prazosin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Prazosin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Prazosin can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Prazosin.Approved, Investigational
PantoprazoleThe serum concentration of Prazosin can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Prazosin is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Prazosin.Approved
ParoxetineThe serum concentration of Prazosin can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Prazosin.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Prazosin.Approved, Vet Approved
PentoliniumPrazosin may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Prazosin.Approved, Investigational
PerhexilinePrazosin may increase the hypotensive activities of Perhexiline.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Prazosin.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Prazosin.Withdrawn
PhenobarbitalThe serum concentration of Prazosin can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzaminePrazosin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Prazosin.Withdrawn
PhentolaminePrazosin may increase the hypotensive activities of Phentolamine.Approved
PhenylephrinePrazosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolaminePrazosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Prazosin.Approved, Vet Approved
PimozideThe serum concentration of Prazosin can be increased when it is combined with Pimozide.Approved
PinacidilPrazosin may increase the hypotensive activities of Pinacidil.Withdrawn
PinaveriumPrazosin may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Prazosin is combined with Pipamperone.Approved
PirbuterolPrazosin may decrease the vasoconstricting activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Prazosin.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Prazosin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Prazosin.Withdrawn
Platelet Activating FactorThe serum concentration of Prazosin can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazidePrazosin may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Prazosin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Prazosin.Approved
PosaconazoleThe serum concentration of Prazosin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Prazosin is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Prazosin.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Prazosin.Approved, Vet Approved
PregabalinPrazosin may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenylaminePrazosin may increase the hypotensive activities of Prenylamine.Withdrawn
PrimidonePrimidone may increase the hypotensive activities of Prazosin.Approved, Vet Approved
ProbenecidThe serum concentration of Prazosin can be increased when it is combined with Probenecid.Approved
ProcaterolPrazosin may decrease the vasoconstricting activities of Procaterol.Approved
ProgesteroneThe serum concentration of Prazosin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Prazosin can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Prazosin can be increased when it is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Prazosin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Investigational
ProtriptylineThe serum concentration of Prazosin can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Prazosin.Approved
PseudoephedrinePrazosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuercetinThe serum concentration of Prazosin can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Prazosin is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Prazosin can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Prazosin can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Prazosin.Approved
RacepinephrinePrazosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopaminePrazosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Prazosin.Approved
RanitidineThe serum concentration of Prazosin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Prazosin.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Prazosin.Approved
ReboxetineThe serum concentration of Prazosin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Prazosin can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Prazosin is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Prazosin.Approved
RescinnaminePrazosin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Prazosin.Approved
RifampicinThe serum concentration of Prazosin can be decreased when it is combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Prazosin.Approved, Investigational
RilmenidinePrazosin may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Prazosin can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Prazosin is combined with Riociguat.Approved
RisedronatePrazosin may increase the hypotensive activities of Risedronate.Approved, Investigational
RisperidonePrazosin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronPrazosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrinePrazosin may decrease the vasoconstricting activities of Ritodrine.Approved
RitonavirThe serum concentration of Prazosin can be decreased when it is combined with Ritonavir.Approved, Investigational
RituximabPrazosin may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Prazosin.Approved
RolapitantThe serum concentration of Prazosin can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Prazosin.Approved, Investigational
RomifidinePrazosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe risk or severity of adverse effects can be increased when Prazosin is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Prazosin is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Prazosin is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Prazosin is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Prazosin.Withdrawn
SalbutamolPrazosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Prazosin.Approved, Vet Approved
SalmeterolPrazosin may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanPrazosin may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Prazosin can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Prazosin can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Prazosin.Approved, Vet Approved
SelegilineThe serum concentration of Prazosin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Prazosin.Approved
SertralineThe serum concentration of Prazosin can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Prazosin is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Prazosin.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Prazosin.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Prazosin.Approved
SimvastatinThe serum concentration of Prazosin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Prazosin can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Prazosin.Approved, Investigational
SitaxentanPrazosin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Prazosin is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Prazosin.Approved
SolabegronPrazosin may decrease the vasoconstricting activities of Solabegron.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Prazosin.Approved, Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Prazosin.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Prazosin.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Prazosin.Experimental
SpiraprilPrazosin may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Prazosin.Approved
SR 58611Prazosin may decrease the vasoconstricting activities of SR 58611.Investigational
St. John's WortThe serum concentration of Prazosin can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Prazosin can be increased when it is combined with Staurosporine.Experimental
StreptokinaseThe risk or severity of adverse effects can be increased when Prazosin is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Prazosin can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Prazosin is combined with Sufentanil.Approved, Investigational
SulfinpyrazoneThe serum concentration of Prazosin can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Prazosin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Prazosin can be increased when it is combined with Sunitinib.Approved, Investigational
SynephrinePrazosin may decrease the vasoconstricting activities of Synephrine.Experimental
TacrineThe serum concentration of Prazosin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Prazosin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Prazosin.Approved, Investigational
TamoxifenThe serum concentration of Prazosin can be decreased when it is combined with Tamoxifen.Approved
TamsulosinPrazosin may increase the antihypertensive activities of Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Prazosin.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Prazosin.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Prazosin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Prazosin is combined with Telmisartan.Approved, Investigational
TemocaprilPrazosin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Prazosin.Approved
TerazosinPrazosin may increase the antihypertensive activities of Terazosin.Approved
TerbutalinePrazosin may decrease the vasoconstricting activities of Terbutaline.Approved
TerfenadineThe serum concentration of Prazosin can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Prazosin can be increased when it is combined with Teriflunomide.Approved
TerlipressinPrazosin may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe serum concentration of Prazosin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Prazosin can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Prazosin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Prazosin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Prazosin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Prazosin is combined with Thioridazine.Approved
TibolonePrazosin may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Prazosin.Approved
TicrynafenPrazosin may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Prazosin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Tizanidine.Approved
TolazolinePrazosin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Prazosin is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidPrazosin may increase the hypotensive activities of Tolfenamic Acid.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Prazosin.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Prazosin.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Prazosin.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Prazosin.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Prazosin.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Trandolapril.Approved
TranilastPrazosin may increase the hypotensive activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Prazosin.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Prazosin.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Prazosin.Approved
TravoprostTravoprost may increase the hypotensive activities of Prazosin.Approved
TrazodoneThe serum concentration of Prazosin can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Prazosin.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Prazosin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Prazosin.Approved
TrichlormethiazidePrazosin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Prazosin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Prazosin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinPrazosin may increase the antihypertensive activities of Trimazosin.Experimental
TrimethaphanPrazosin may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimThe serum concentration of Prazosin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Prazosin can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Prazosin can be increased when it is combined with Troleandomycin.Approved
TulobuterolPrazosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Prazosin.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Prazosin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Prazosin.Approved
UnoprostonePrazosin may increase the hypotensive activities of Unoprostone.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Prazosin.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Prazosin.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Prazosin.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Prazosin.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Prazosin.Approved
VerapamilThe risk or severity of adverse effects can be increased when Prazosin is combined with Verapamil.Approved
VinblastineThe serum concentration of Prazosin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Prazosin.Approved, Investigational
VincristineThe serum concentration of Prazosin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Prazosin can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetinePrazosin may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Prazosin.Approved
XylazinePrazosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolinePrazosin may increase the hypotensive activities of Xylometazoline.Approved
YM-178Prazosin may decrease the vasoconstricting activities of YM-178.Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Prazosin.Approved, Vet Approved
ZiconotidePrazosin may increase the hypotensive activities of Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Prazosin.Approved
ZimelidineThe serum concentration of Prazosin can be increased when it is combined with Zimelidine.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take without regard to meals.
References
Synthesis Reference

Stig O. E. Lindholm, “A process for the preparation of anhydrous, stable, crystalline delta-form of prazosin hydrochloride.” U.S. Patent US4873330, issued 0000.

US4873330
General References
  1. Bawaskar HS, Bawaskar PH: Utility of scorpion antivenin vs prazosin in the management of severe Mesobuthus tamulus (Indian red scorpion) envenoming at rural setting. J Assoc Physicians India. 2007 Jan;55:14-21. [PubMed:17444339 ]
  2. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301 ]
  3. Hiraoka Y, Taniguchi T, Tanaka T, Okada K, Kanamaru H, Muramatsu I: Pharmacological characterization of unique prazosin-binding sites in human kidney. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jul;368(1):49-56. Epub 2003 Jun 25. [PubMed:12827214 ]
  4. Link [Link]
External Links
ATC CodesC02CA01C02LE01
AHFS Codes
  • 24:20.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9479
Caco-2 permeable+0.8298
P-glycoprotein substrateSubstrate0.7193
P-glycoprotein inhibitor INon-inhibitor0.5747
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.6405
CYP450 2C9 substrateNon-substrate0.8773
CYP450 2D6 substrateNon-substrate0.7641
CYP450 3A4 substrateSubstrate0.7577
CYP450 1A2 substrateNon-inhibitor0.8434
CYP450 2C9 inhibitorNon-inhibitor0.9278
CYP450 2D6 inhibitorNon-inhibitor0.9685
CYP450 2C19 inhibitorNon-inhibitor0.9169
CYP450 3A4 inhibitorNon-inhibitor0.7608
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8049
Ames testNon AMES toxic0.5581
CarcinogenicityNon-carcinogens0.9199
BiodegradationNot ready biodegradable0.9818
Rat acute toxicity2.3304 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8352
hERG inhibition (predictor II)Inhibitor0.8489
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pfizer laboratories div pfizer inc
  • American therapeutics inc
  • Clonmel healthcare ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Watson laboratories inc
  • Pfizer inc
Packagers
Dosage forms
FormRouteStrength
TabletOral1 mg
TabletOral2 mg
TabletOral5 mg
CapsuleOral1 mg/1
CapsuleOral2 mg/1
CapsuleOral5 mg/1
Prices
Unit descriptionCostUnit
Minipress 5 mg capsule1.97USD capsule
Minipress 2 mg capsule1.14USD capsule
Prazosin HCl 5 mg capsule0.98USD capsule
Prazosin 5 mg capsule0.94USD capsule
Minipress 1 mg capsule0.83USD capsule
Prazosin HCl 2 mg capsule0.57USD capsule
Prazosin 2 mg capsule0.55USD capsule
Prazosin HCl 1 mg capsule0.41USD capsule
Prazosin 1 mg capsule0.4USD capsule
Apo-Prazo 5 mg Tablet0.4USD tablet
Novo-Prazin 5 mg Tablet0.4USD tablet
Nu-Prazo 5 mg Tablet0.4USD tablet
Vasoflex hd caplet0.38USD caplet
Vasoflex forte capsule0.29USD capsule
Apo-Prazo 2 mg Tablet0.29USD tablet
Novo-Prazin 2 mg Tablet0.29USD tablet
Nu-Prazo 2 mg Tablet0.29USD tablet
Apo-Prazo 1 mg Tablet0.22USD tablet
Novo-Prazin 1 mg Tablet0.22USD tablet
Nu-Prazo 1 mg Tablet0.22USD tablet
Vasoflex tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point279 °CPhysProp
water solubility0.5 mg/mL (HCl salt)Sigma Aldrich
logP1.3Not Available
Caco2 permeability-4.36ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.693 mg/mLALOGPS
logP1.93ALOGPS
logP1.65ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area106.95 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity104.5 m3·mol-1ChemAxon
Polarizability40.49 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Quinazolinamine
  • Quinazoline
  • Dialkylarylamine
  • Anisole
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Primary aromatic amine
  • Heteroaromatic compound
  • Furan
  • Tertiary amine
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Chang HK, Hsu FL, Liu IM, Cheng JT: Stimulatory effect of cinnamic acid analogues on alpha1A-adrenoceptors in-vitro. J Pharm Pharmacol. 2003 Jun;55(6):833-7. [PubMed:12841945 ]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  3. Morris DP, Price RR, Smith MP, Lei B, Schwinn DA: Cellular trafficking of human alpha1a-adrenergic receptors is continuous and primarily agonist-independent. Mol Pharmacol. 2004 Oct;66(4):843-54. Epub 2004 Jul 16. [PubMed:15258254 ]
  4. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
  5. Suzuki Y, Kanada A, Okaya Y, Aisaka K: Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs. Eur J Pharmacol. 2000 Apr 7;394(1):123-30. [PubMed:10771044 ]
  6. Tomiyama Y, Kobayashi K, Tadachi M, Kobayashi S, Inada Y, Kobayashi M, Yamazaki Y: Expressions and mechanical functions of alpha1-adrenoceptor subtypes in hamster ureter. Eur J Pharmacol. 2007 Nov 14;573(1-3):201-5. Epub 2007 Jul 6. [PubMed:17658513 ]
  7. Zacharia J, Hillier C, MacDonald A: Alpha1-adrenoceptor subtypes involved in vasoconstrictor responses to exogenous and neurally released noradrenaline in rat femoral resistance arteries. Br J Pharmacol. 2004 Mar;141(6):915-24. Epub 2004 Feb 23. [PubMed:14980979 ]
  8. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Al-Damluji S, Shen WB, White S, Barnard EA: alpha(1B) adrenergic receptors in gonadotrophin-releasing hormone neurones: relation to Transport-P. Br J Pharmacol. 2001 Jan;132(1):336-44. [PubMed:11156594 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  4. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41. [PubMed:12270758 ]
  5. Sharpe IA, Thomas L, Loughnan M, Motin L, Palant E, Croker DE, Alewood D, Chen S, Graham RM, Alewood PF, Adams DJ, Lewis RJ: Allosteric alpha 1-adrenoreceptor antagonism by the conopeptide rho-TIA. J Biol Chem. 2003 Sep 5;278(36):34451-7. Epub 2003 Jun 24. [PubMed:12824165 ]
  6. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
  7. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Nagaoka Y, Ahmed M, Hossain M, Bhuiyan MA, Ishiguro M, Nakamura T, Watanabe M, Nagatomo T: Amino acids of the human alpha1d-adrenergic receptor involved in antagonist binding. J Pharmacol Sci. 2008 Jan;106(1):114-20. Epub 2008 Jan 11. [PubMed:18187928 ]
  2. Yamamoto Y, Koike K: alpha(1)-Adrenoceptor subtypes in the mouse mesenteric artery and abdominal aorta. Br J Pharmacol. 2001 Nov;134(5):1045-54. [PubMed:11682453 ]
  3. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH6
Uniprot ID:
Q9H252
Molecular Weight:
109923.705 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH7
Uniprot ID:
Q9NS40
Molecular Weight:
134998.525 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Pan G, Winter TN, Roberts JC, Fairbanks CA, Elmquist WF: Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells. Mol Pharm. 2010 Feb 1;7(1):138-45. doi: 10.1021/mp900177r. [PubMed:19886673 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  3. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783 ]
  4. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  5. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV: Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9. [PubMed:9380680 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  2. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. [PubMed:11437380 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23